News

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign-up now to receive our weekly R&D News Roundup email. COVID-19 vaccine trials in the United States, several of which are now in phase 3, have so far not included pregnant women or women who are breastfeeding, and only one potential US-market vaccine manufacturer—AstraZeneca—has begun testing in children. Vaccine candidates are customarily tested first in healthy adults, the population deemed most likely to provide clear results on vaccine efficacy and be at lowest risk for side effects, often leaving out younger populations and women who are pregnant. As manufacturers have been starting to broaden their volunteer pools to other typically underrepresented and at-risk populations—for example, adults over the age of 65 and people with HIV—some experts and advocates remain concerned about the lack of data regarding pregnant women and children.The US Food and Drug Administration (FDA) recently granted emergency use authorization (EUA) to SalivaDirect, a saliva-based COVID-19 diagnostic test developed by researchers at the Yale School of Public Health and funded by the National Basketball Association (NBA). The test joins several other saliva-based tests that have been greenlit by FDA in recent months. SalivaDirect’s Yale-based research team is now working with other labs to develop more saliva-based diagnostics, including one developed at the University of Illinois at Urbana-Champaign, which also received EUA last week. Researchers hope that increased availability of saliva-based tests—which often do not require administration by a trained health care worker and cost less than the standard nasopharyngeal swab tests—will improve speed and affordability of COVID-19 detection.Pharmaceutical companies and research centers, supported by the European Union (EU), have created a 37-member initiative working to advance research and development (R&D) to combat the COVID-19 pandemic. Called the Corona Accelerated R&D in Europe (CARE) initiative, the research-focused consortium has three main goals: screen libraries to identify existing compounds that have potential to be repurposed against COVID-19, perform in silico screening to find new small molecules that fight SARS-CoV-2, and apply approaches like fully human phage and yeast display to the discovery of virus-neutralizing antibodies. The initiative is one of several organizational collaborations working on strategies against COVID-19 and will work to ensure its efforts integrate with and complement other programs, with plans to operate for the next five years.

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign-up now to receive our weekly R&D News Roundup email. Researchers in Rwanda, amid insufficient COVID-19 testing capacity, have created an algorithm to maximize the efficiency of pooled testing—the method of testing batches of samples first, followed by individual sample testing if a batch test comes back positive. Instead of retesting every individual sample after a batch test comes back positive, the new algorithm indicates a way to create and overlap smaller groups from the batch that will lead to identification of the positive samples. While the complexity of the method is of concern to some researchers, the approach also shows potential to be an important tool for resource-limited settings battling the COVID-19 pandemic, given the reduction in total number of required retests and the speed of results. The algorithm is currently being developed into a software that can be used by lab technicians to minimize human error.A research team at the University of California, San Francisco (UCSF), synthesized an anti-coronavirus compound similar to an infection-fighting antibody found in llamas, alpacas, and other camelids. The molecule, a type of nanobody, is among the most potent compounds for fighting COVID-19 identified in lab tests to date, according to the researchers, although it has yet to go through animal studies or human clinical trials. Nanobodies are about a quarter of the size of most antibodies, and work by nestling into small spaces in proteins and blocking viruses from attaching to and infecting cells. The nanobody made in the UCSF lab is stable enough to be converted into a dry powder and aerosolized, with potential to be self-administered by simple inhaled sprays to the nose and lungs. The researchers have published their lab results in a preprinted, non-peer reviewed paper and are in the process of finding a partner to assist in clinical testing, manufacturing, and distributing the compound.The Africa Centers for Disease Control and Prevention (CDC) announced Thursday the launch of a continent-wide study of COVID-19 antibodies, after a smaller study and testimony from global health experts indicated that current official numbers might be underestimating infection and death rates. With a median age of 19, Africa’s young population might be indicative of high levels of asymptomatic infection. The study, to begin in the upcoming weeks, will include all countries in Africa, likely starting with Liberia, Sierra Leone, Zambia, Zimbabwe, Cameroon, Nigeria, and Morocco. The continent surpassed 1 million confirmed cases on August 7, with more than 24,000 deaths recorded.

In recognition of World Mosquito Day 2020, GHTC is testing our readers’ knowledge of mosquito-borne diseases and ongoing efforts to develop treatments, vaccines, vector-control innovations, and other tools to outsmart the world’s deadliest animal.Find out if you have achieved mozzie mastery by taking our quiz below.Loading...(function(i,s,o,g,r,a,m){var ql=document.querySelectorAll('A[quiz],DIV[quiz],A[data-quiz],DIV[data-quiz]'); if(ql){if(ql.length){for(var k=0;k